DOSSIER · 13F-HR · Q2 2026

Kynam Capital Management, LP

$1.8B in tracked AUM across 32 positions as of Q2 2026.

KC
CIK 0001907884 · last filed Jun 30, 2026
Total AUM
$1.8B
as of Q2 2026
Holdings
32
positions
Whale Score
72
72
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

Kynam Capital Management's 13F filing for the period ending September 30, 2025, reveals a concentrated, high-conviction investment strategy focused entirely on the healthcare sector. The firm saw substantial growth in assets under management (AUM), with the total portfolio value increasing by 28.6% from approximately $928.82 million to $1.19 billion. Despite the significant capital inflow or appreciation, the fund maintains a relatively compact portfolio of 27 holdings.

...

Key Holdings

The portfolio is dominated by mid-to-large cap biotechnology companies, with the top five positions all representing double-digit percentage allocations.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
CLDX
CELLDEX THERAPEUTICS INC NEW
$198M5.3M10.9%
02
SNDX
SYNDAX PHARMACEUTICALS INC
$176M8.1M9.7%
03
PCVX
VAXCYTE INC
$170M2.9M9.4%
04
COGT
COGENT BIOSCIENCES INC
$142M3.7M7.8%
05
VERA
VERA THERAPEUTICS INC
$124M2.9M6.9%
06
VRDN
VIRIDIAN THERAPEUTICS INC
$119M6.5M6.6%
07
TVTX
TRAVERE THERAPEUTICS INC
$114M2.0M6.3%
08
BEAM
BEAM THERAPEUTICS INC
$97M2.8M5.4%
09
M96088105
UROGEN PHARMA LTD
$90M2.4M5.0%
10
LEGN
LEGEND BIOTECH CORP
$87M3.0M4.8%

Filing history

2026Q2Jun 30
$1.8B 11.6%
32 positionsView →
2026Q1Mar 31
$1.6B 3.6%
39 positionsView →
2025Q4Dec 31
$1.6B 31.1%
37 positionsView →
2025Q3Sep 30
$1.2B 28.6%
27 positionsView →
2025Q2Jun 30
$929M 6.8%
31 positionsLocked
2025Q1Mar 31
$870M 48.6%
23 positionsLocked
2024Q4Dec 31
$1.7B 29.7%
30 positionsLocked
2024Q3Sep 30
$1.3B 0.6%
25 positionsLocked
2024Q2Jun 30
$1.3B 35.7%
26 positionsLocked
2024Q1Mar 31
$955M 5.9%
23 positionsLocked
2023Q4Dec 31
$903M 47.6%
24 positionsLocked
2023Q3Sep 30
$611M 15.9%
30 positionsLocked
Showing 12 of 19